Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.26B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$2.12B |
| 3 |
Apple
AAPL
|
+$986M |
| 4 |
Amazon
AMZN
|
+$676M |
| 5 |
Kenvue
KVUE
|
+$501M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.26B |
| 2 |
iShares MSCI EAFE ETF
EFA
|
+$638M |
| 3 |
Microsoft
MSFT
|
+$630M |
| 4 |
Meta Platforms (Facebook)
META
|
+$578M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$453M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 2.36% |
| 2 | Consumer Discretionary | 1.65% |
| 3 | Financials | 1.08% |
| 4 | Healthcare | 0.89% |
| 5 | Communication Services | 0.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11026
CALL
Cato Corp
CATO
$55.3M
| $77.4K | ﹤0.01% |
+10,100
| New | +$80.4K |
|
|
QNTM
11027
Quantum Biopharma Class B Subordinate Voting Shares
QNTM
$129
| $77.3K | ﹤0.01% |
983
+99
| +11% | +$8.08K |
|
11028
HF Foods Group
HFFG
$99.7M
| $77.2K | ﹤0.01% |
19,458
+5,853
| +43% | +$27.9K |
|
11029
CALL
Abeona Therapeutics
ABEO
$344M
| $77K | ﹤0.01% |
+18,300
| New | +$69.2K |
|
|
SIEN
11030
PUT
DELISTED
Sientra, Inc.
SIEN
| $77K | ﹤0.01% |
27,700
-5,000
| -15% | -$15.4K |
|
11031
Mind CTI
MNDO
$20M
| $77K | ﹤0.01% |
41,178
+21,700
| +111% | +$41.7K |
|
11032
CALL
MacroGenics
MGNX
$257M
| $76.9K | ﹤0.01% |
+16,500
| New | +$82.1K |
|
11033
PUT
Holley
HLLY
$347M
| $76.8K | ﹤0.01% |
15,400
-5,100
| -25% | -$28.9K |
|
11034
PUT
IRIDEX
IRIX
$12.3M
| $76.7K | ﹤0.01% |
+30,200
| New | +$57.3K |
|
11035
SKYX Platforms
SKYX
$169M
| $76.7K | ﹤0.01% |
53,994
-38,571
| -42% | -$74K |
|
11036
CALL
AC Immune
ACIU
$283M
| $76.4K | ﹤0.01% |
26,800
+3,300
| +14% | +$10K |
|
11037
PUT
Ribbon Communications
RBBN
$363M
| $76.4K | ﹤0.01% |
28,500
+800
| +3% | +$2.34K |
|
|
LOMA
11038
CALL
Loma Negra
LOMA
$1.13B
| $76K | ﹤0.01% |
+12,600
| New | +$81.1K |
|
|
EXAI
11039
CALL
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $75.9K | ﹤0.01% |
+16,800
| New | +$109K |
|
|
GLV
11040
Clough Global Dividend & Income Fund
GLV
$76.1M
| $75.8K | ﹤0.01% |
+15,251
| New | +$83K |
|
11041
CALL
Karyopharm Therapeutics
KPTI
$44.5M
| $75.6K | ﹤0.01% |
3,760
+460
| +14% | +$10.3K |
|
|
LILM
11042
DELISTED
Lilium N.V. Class A Ordinary Shares
LILM
| $75.5K | ﹤0.01% |
105,883
-114,289
| -52% | -$134K |
|
11043
CALL
Hydrofarm Holdings
HYFM
$4.22M
| $75.5K | ﹤0.01% |
6,190
-6,890
| -53% | -$76.9K |
|
11044
SelectQuote
SLQT
$97.1M
| $75.2K | ﹤0.01% |
64,273
-33,574
| -34% | -$50.7K |
|
11045
CALL
TherapeuticsMD
TXMD
$26.4M
| $75.2K | ﹤0.01% |
24,900
-3,000
| -11% | -$11.4K |
|
11046
PUT
Black Diamond Therapeutics
BDTX
$130M
| $75.2K | ﹤0.01% |
26,200
-17,700
| -40% | -$65.2K |
|
11047
PUT
Santander
BSBR
$43.5B
| $74.9K | ﹤0.01% |
+14,600
| New | +$82.7K |
|
11048
CALL
Zevia
ZVIA
$101M
| $74.8K | ﹤0.01% |
33,700
-9,700
| -22% | -$28.5K |
|
11049
CEL-SCI Corp
CVM
$28.3M
| $74.7K | ﹤0.01% |
1,991
-4,012
| -67% | -$192K |
|
11050
Minerva Neurosciences
NERV
$259M
| $74.5K | ﹤0.01% |
+10,804
| New | +$96.8K |
|
Similar funds
Jeff Yass's Q3 2023 Portfolio in Review
As of Q3 2023, Jeff Yass held 13,532 positions worth $481B, down 2.3% from $492B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass's Q3 2023 filing shows 1,585 new, 5,250 increased, 4,926 reduced and 1,614 closed positions. Its largest new stake was iShares JPMorgan USD Emerging Markets Bond ETF: 632,356 shares worth $52.2M. The largest sale was NVIDIA, an estimated $1.26B.
By sector, the portfolio is most concentrated in Technology at 2.4% of assets, down from 2.7% a quarter earlier, followed by Consumer Discretionary and Financials.
- Jeff Yass's largest Q3 2023 buy was iShares JPMorgan USD Emerging Markets Bond ETF: 632,356 shares worth $52.2M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q3 2023, an estimated $3.26B increase.
- Jeff Yass's biggest Q3 2023 reduction was NVIDIA, cutting an estimated $1.26B.
- Jeff Yass fully exited Magellan Midstream Partners, L.P. in Q3 2023, selling an estimated $45.6M.
- Jeff Yass's ten largest holdings make up 28% of its $481B portfolio in Q3 2023.
- Jeff Yass opened 1,585 new positions and closed 1,614 in Q3 2023.
- Jeff Yass's portfolio value fell 2.3% quarter-over-quarter to $481B.
Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.